The Role of Nuclear Insulin and IGF1 Receptors in Metabolism and Cancer.


Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
02 04 2021
Historique:
received: 01 03 2021
revised: 24 03 2021
accepted: 01 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 18 9 2021
Statut: epublish

Résumé

Insulin (InsR) and insulin-like growth factor-1 (IGF1R) receptors mediate the metabolic and growth-promoting actions of insulin and IGF1/IGF2, respectively. Evidence accumulated in recent years indicates that, in addition to their typical cell-surface localization pattern and ligand-activated mechanism of action, InsR and IGF1R are present in the cell nucleus of both normal and transformed cells. Nuclear translocation seems to involve interaction with a small, ubiquitin-like modifier protein (SUMO-1), although this modification is not always a prerequisite. Nuclear InsR and IGF1R exhibit a number of biological activities that classically fit within the definition of transcription factors. These nuclear activities include, among others, sequence-specific DNA binding and transcriptional control. Of particular interest, nuclear IGF1R was capable of binding and stimulating its cognate gene promoter. The physiological relevance of this autoregulatory mechanism needs to be further investigated. In addition to its nuclear localization, studies have identified IGF1R in the Golgi apparatus, and this particular distribution correlated with a migratory phenotype. In summary, the newly described roles of InsR and IGF1R as gene regulators, in concert with their atypical pattern of subcellular distribution, add a further layer of complexity to traditional models of cell signaling. Furthermore, and in view of the emerging role of IGF1R as a potential therapeutic target, a better understanding of the mechanisms responsible for nuclear IGF1R transport and identification of IGF1R interactors might help optimize target directed therapies in oncology.

Identifiants

pubmed: 33918477
pii: biom11040531
doi: 10.3390/biom11040531
pmc: PMC8065599
pii:
doi:

Substances chimiques

Receptor, IGF Type 1 EC 2.7.10.1
Receptor, Insulin EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Références

Horm Cancer. 2018 Jun;9(3):205-214
pubmed: 29524179
Eur J Cancer. 2012 Nov;48(16):3027-35
pubmed: 22682017
J Biol Chem. 1978 Apr 10;253(7):2098-103
pubmed: 24634
Oncotarget. 2016 Jul 5;7(27):42288-42302
pubmed: 27275536
Nat Cell Biol. 2001 Sep;3(9):802-8
pubmed: 11533659
Biochim Biophys Acta Mol Cell Res. 2018 Jun;1865(6):920-931
pubmed: 29621572
Cell. 2019 Apr 18;177(3):722-736.e22
pubmed: 30955890
Curr Opin Cell Biol. 2015 Aug;35:137-43
pubmed: 26057614
Endocrinol Metab Clin North Am. 2012 Jun;41(2):231-47, v
pubmed: 22682628
Cancer Lett. 2018 Apr 28;420:146-155
pubmed: 29421153
Mutat Res. 2020 Apr - Jun;784:108307
pubmed: 32430099
Oncogene. 2015 Apr 23;34(17):2227-38
pubmed: 24909165
Biochem J. 1997 Oct 1;327 ( Pt 1):209-15
pubmed: 9355755
Lancet Oncol. 2012 Dec;13(12):e537-44
pubmed: 23182194
Oncogene. 2010 Jul 15;29(28):3997-4006
pubmed: 20473332
Mol Cancer Res. 2013 Nov;11(11):1303-13
pubmed: 23928059
PLoS One. 2017 Dec 18;12(12):e0189087
pubmed: 29253018
Growth Horm IGF Res. 2014 Aug;24(4):112-8
pubmed: 24863809
Genes Dev. 2011 May 15;25(10):1078-90
pubmed: 21576267
PLoS One. 2012;7(4):e34173
pubmed: 22506015
Nature. 1977 Oct 20;269(5630):698-700
pubmed: 593329
Pediatr Endocrinol Rev. 2015 Dec;13(2):521-30
pubmed: 26841640
Science. 2003 Feb 28;299(5611):1342-6
pubmed: 12610293
J Biol Chem. 1987 Mar 5;262(7):3362-8
pubmed: 3546306
J Biol Chem. 2012 Jan 20;287(4):2766-76
pubmed: 22128190
Cell. 1993 Oct 8;75(1):73-82
pubmed: 8402902
J Cell Physiol. 2013 Apr;228(4):675-9
pubmed: 22926508
PLoS One. 2012;7(8):e42483
pubmed: 22879999
Cold Spring Harb Perspect Biol. 2013 Nov 01;5(11):a016790
pubmed: 24186068
Cancer Res. 2018 Jul 1;78(13):3497-3509
pubmed: 29735545
J Mol Endocrinol. 2018 Jul;61(1):T115-T137
pubmed: 29626053
Biochem Biophys Res Commun. 2011 Jan 14;404(2):667-71
pubmed: 21147068
Oncology. 2002;63(4):317-32
pubmed: 12417786
PLoS One. 2020 Jul 23;15(7):e0236291
pubmed: 32701997
J Biol Chem. 1978 Jun 10;253(11):4058-66
pubmed: 206561
Cells. 2020 Apr 02;9(4):
pubmed: 32252327
Nat Rev Drug Discov. 2002 Oct;1(10):769-83
pubmed: 12360255
J Biol Chem. 2002 Oct 18;277(42):39684-95
pubmed: 12138094
J Lab Clin Med. 1957 Jun;49(6):825-36
pubmed: 13429201
Sci Rep. 2018 Mar 12;8(1):4378
pubmed: 29531349
Endocr Rev. 2009 Oct;30(6):586-623
pubmed: 19752219
Sci Signal. 2010 Feb 09;3(108):ra10
pubmed: 20145208
J Cell Physiol. 2017 Oct;232(10):2722-2730
pubmed: 28112398
Front Endocrinol (Lausanne). 2017 Nov 28;8:332
pubmed: 29234306
Arch Physiol Biochem. 2008 Feb;114(1):17-22
pubmed: 18465355
Exp Ther Med. 2016 Oct;12(4):2275-2280
pubmed: 27698723
Sci Signal. 2020 May 26;13(633):
pubmed: 32457113
J Cell Physiol. 1978 Oct;97(1):37-47
pubmed: 361751
N Engl J Med. 2003 Dec 4;349(23):2184-6
pubmed: 14657423
J Biol Chem. 2008 Jan 4;283(1):398-404
pubmed: 17965019
Endocrinology. 2013 May;154(5):1672-9
pubmed: 23507573
Mol Cell Endocrinol. 2006 Jun 27;252(1-2):241-6
pubmed: 16647191
Mol Cell Biol. 2003 May;23(9):3363-72
pubmed: 12697834
J Endocrinol. 2006 Dec;191(3):605-12
pubmed: 17170218
PLoS One. 2017 Sep 25;12(9):e0185164
pubmed: 28945762
Nat Rev Cancer. 2014 May;14(5):329-41
pubmed: 24722429
Cancer Lett. 1996 Jul 19;105(1):51-9
pubmed: 8689633
Br J Cancer. 2017 Dec 5;117(12):1777-1786
pubmed: 29123263
Mol Genet Metab. 2019 Mar;126(3):259-265
pubmed: 30639046
Biochem J. 1990 Sep 1;270(2):383-90
pubmed: 1698059
Mol Endocrinol. 2003 Mar;17(3):472-86
pubmed: 12554758
Cancers (Basel). 2010 Mar 25;2(2):233-61
pubmed: 24281069
Front Endocrinol (Lausanne). 2021 Jan 29;11:620013
pubmed: 33584548
Oncotarget. 2020 Jun 23;11(25):2424-2437
pubmed: 32637033
J Biol Chem. 2012 Jun 8;287(24):19827-40
pubmed: 22514272
EMBO Rep. 2012 Mar 01;13(3):244-50
pubmed: 22261717
Neuroendocrinology. 2006;83(3-4):154-60
pubmed: 17047378
Pediatr Endocrinol Rev. 2008 Feb;5 Suppl 2:739-43
pubmed: 18317445
Cancer Res. 2010 Aug 15;70(16):6412-9
pubmed: 20710042
Proc Natl Acad Sci U S A. 1976 May;73(5):1427-31
pubmed: 179086
Cells. 2020 May 20;9(5):
pubmed: 32443727
Adv Enzyme Regul. 2006;46:163-75
pubmed: 16857240
Am J Transl Res. 2009 Mar 08;1(3):249-58
pubmed: 19956435
N Engl J Med. 2004 Feb 5;350(6):570-7
pubmed: 14762184

Auteurs

Haim Werner (H)

Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
Shalom and Varda Yoran Institute for Human Genome Research, Tel Aviv University, Tel Aviv 69978, Israel.

Rive Sarfstein (R)

Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.

Zvi Laron (Z)

Endocrine and Diabetes Research Unit, Schneider Children's Medical Center, Petah Tikva 49292, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH